VentureBeat

TODAY’S HEADLINES:

• Elixir Pharma sets IPO range, seeks up to $92M for anti-aging drugs (Edgar)
• Deltanoid Pharma raises $12M for kidney drugs (PDF release)
• CovX, cancer and diabetes-drug biotech, acquired by Pfizer (release)
• Affymetrix pays $75M for reagent maker USB (release)
• Merrion Pharma postpones U.S. IPO, raises €5.6M in Dublin offering (Irish Independent)
• Isis spinout Altair raising first round for asthma drugs (release)
• “Human hydration” sensor maker Cantimer names Robin Stracey CEO (release)
• Sensimed raises CHF 8M for glaucoma diagnostics (PE Hub)

Deltanoid Pharma raises $12M for kidney drugs — Deltanoid Pharmaceuticals, a Madison, Wis., drug developer focused on new forms of vitamin D for use against kidney disease, raised $12 million in a second funding round. The company’s PDF release is here.

Investors in the round included the Wisconsin Alumni Research Foundation (WARF), a tech-transfer organization associated with the University of Wisconsin, and two VC firms, Mason Wells and Venture Investors. Deltanoid is developing new “analogues” of the vitamin D molecule with possible utility in treating osteoporosis and kidney disease. The company has licensed one drug candidate to Pfizer, and so far has raised a total of $16 million.

CovX, cancer and diabetes-drug biotech, acquired by Pfizer — CovX, a La Jolla, Calif., biotech developing synthetic molecules with potential uses in treating cancer and diabetes, was acquired by Pfizer as part of the drugmaker’s expansion into biotech. Terms of the acquisition weren’t disclosed; the release is here.

CovX has been pursuing an interesting attempt to build new drugs out of the short protein fragments known as peptides. While peptides can have potent drug-like effects against various biological “target” molecules, they are often broken down quickly in the body. CovX has developed a new class of molecules that it calls — a bit too cutely — CovX-bodies, which purportedly combine the efficacy of peptides with the longer lasting effects of monoclonal antibodies, although of course it doesn’t specify exactly how.

The company’s pipeline includes two inhibitors of angiogenesis — or blood-vessel formation — which might be useful in treating cancer, as well as molecules that mimic metabolic processes that go awry in diabetes. None of its drug candidates have yet entered human testing.

ProCertus BioPharm, a Madison, Wis., company developing drugs to minimize the side effects of radiation and chemotherapy, raised $2.3 million in a first round of financing. The company will use the money to begin human tests of products such as DermX, which is supposed to prevent radiation-therapy induced dermatitis.

The round was led by Venture Investors, a significant Midwest-based healthcare and IT venture firm. Existing investors including the Novartis Venture Fund also joined the round.

These are serious players who presumably don’t throw their money around lightly, so it’s probably not wise to draw too many conclusions from ProCertus’ kitschy Web site, which is not only outdated (it refers to clinical trials planned for 2006 that apparently haven’t yet started) but inaccurate (it states that there are no competing products for treatment or prevention of cancer-treatment induced hair loss, dermatitis, or mucositis, a claim with which the folks at Amgen would presumably take issue).

The company’s announcement is here.

TomoTherapy, a Madison, Wis.-based maker of imaging and radiation-treatment systems for cancer therapy, raised $222.3 million in an initial offering after its shares priced higher than the company’s original range.

TomoTherapy shares, which now trade under the symbol TTPY, priced at $19, well above the company’s expected range of $15 to $17, yielding net proceeds to the company of roughly $185 million. The stock opened this morning at $24. TomoTherapy makes and sells integrated devices that provide radiation treatment for cancer guided by a built-in CT scanner.

Here’s the company’s announcement. TomoTherapy had previously raised approximately $79 million in venture capital from the likes of Venture Investors, Avalon Technology, the Endeavors Group, Open Prairie Ventures, Ascension Health Ventures and the Wisconsin Alumni Research Foundation, according to PE Wire.